316 related articles for article (PubMed ID: 36674430)
1. Emerging Hallmarks of Metabolic Reprogramming in Prostate Cancer.
Lasorsa F; di Meo NA; Rutigliano M; Ferro M; Terracciano D; Tataru OS; Battaglia M; Ditonno P; Lucarelli G
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674430
[TBL] [Abstract][Full Text] [Related]
2. Novel Strategy of Proxalutamide for the Treatment of Prostate Cancer through Coordinated Blockade of Lipogenesis and Androgen Receptor Axis.
Gu Y; Xue M; Wang Q; Hong X; Wang X; Zhou F; Sun J; Wang G; Peng Y
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948018
[No Abstract] [Full Text] [Related]
3. A review on the interactions between the tumor microenvironment and androgen receptor signaling in prostate cancer.
McAllister MJ; Underwood MA; Leung HY; Edwards J
Transl Res; 2019 Apr; 206():91-106. PubMed ID: 30528321
[TBL] [Abstract][Full Text] [Related]
4. Metabolic changes during prostate cancer development and progression.
Beier AK; Puhr M; Stope MB; Thomas C; Erb HHH
J Cancer Res Clin Oncol; 2023 May; 149(5):2259-2270. PubMed ID: 36151426
[TBL] [Abstract][Full Text] [Related]
5. Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells.
Shafi AA; Putluri V; Arnold JM; Tsouko E; Maity S; Roberts JM; Coarfa C; Frigo DE; Putluri N; Sreekumar A; Weigel NL
Oncotarget; 2015 Oct; 6(31):31997-2012. PubMed ID: 26378018
[TBL] [Abstract][Full Text] [Related]
6. Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome.
Leach DA; Need EF; Toivanen R; Trotta AP; Palethorpe HM; Tamblyn DJ; Kopsaftis T; England GM; Smith E; Drew PA; Pinnock CB; Lee P; Holst J; Risbridger GP; Chopra S; DeFranco DB; Taylor RA; Buchanan G
Oncotarget; 2015 Jun; 6(18):16135-50. PubMed ID: 25965833
[TBL] [Abstract][Full Text] [Related]
7. Androgen-induced expression of DRP1 regulates mitochondrial metabolic reprogramming in prostate cancer.
Lee YG; Nam Y; Shin KJ; Yoon S; Park WS; Joung JY; Seo JK; Jang J; Lee S; Nam D; Caino MC; Suh PG; Chan Chae Y
Cancer Lett; 2020 Feb; 471():72-87. PubMed ID: 31838085
[TBL] [Abstract][Full Text] [Related]
8. Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer.
Shiota M; Yokomizo A; Naito S
Free Radic Biol Med; 2011 Oct; 51(7):1320-8. PubMed ID: 21820046
[TBL] [Abstract][Full Text] [Related]
9. Functional genomic studies reveal the androgen receptor as a master regulator of cellular energy metabolism in prostate cancer.
Gonthier K; Poluri RTK; Audet-Walsh É
J Steroid Biochem Mol Biol; 2019 Jul; 191():105367. PubMed ID: 31051242
[TBL] [Abstract][Full Text] [Related]
10. Local endocrine, paracrine and redox signaling networks impact estrogen and androgen crosstalk in the prostate cancer microenvironment.
Grubisha MJ; DeFranco DB
Steroids; 2013 Jun; 78(6):538-41. PubMed ID: 23380371
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor moonlighting in the prostate cancer microenvironment.
Cioni B; Zwart W; Bergman AM
Endocr Relat Cancer; 2018 Jun; 25(6):R331-R349. PubMed ID: 29618577
[TBL] [Abstract][Full Text] [Related]
12. The NLR-related protein NWD1 is associated with prostate cancer and modulates androgen receptor signaling.
Correa RG; Krajewska M; Ware CF; Gerlic M; Reed JC
Oncotarget; 2014 Mar; 5(6):1666-82. PubMed ID: 24681825
[TBL] [Abstract][Full Text] [Related]
13. Stromal TGF-β signaling induces AR activation in prostate cancer.
Yang F; Chen Y; Shen T; Guo D; Dakhova O; Ittmann MM; Creighton CJ; Zhang Y; Dang TD; Rowley DR
Oncotarget; 2014 Nov; 5(21):10854-69. PubMed ID: 25333263
[TBL] [Abstract][Full Text] [Related]
14. Sin1 promotes proliferation and invasion of prostate cancer cells by modulating mTORC2-AKT and AR signaling cascades.
Huang Y; Feng G; Cai J; Peng Q; Yang Z; Yan C; Yang L; Wang Z
Life Sci; 2020 May; 248():117449. PubMed ID: 32088212
[TBL] [Abstract][Full Text] [Related]
15. Tumour metabolism and its unique properties in prostate adenocarcinoma.
Bader DA; McGuire SE
Nat Rev Urol; 2020 Apr; 17(4):214-231. PubMed ID: 32112053
[TBL] [Abstract][Full Text] [Related]
16. MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT.
Shen T; Wang W; Zhou W; Coleman I; Cai Q; Dong B; Ittmann MM; Creighton CJ; Bian Y; Meng Y; Rowley DR; Nelson PS; Moore DD; Yang F
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586682
[TBL] [Abstract][Full Text] [Related]
17. The role of androgens and the androgen receptor in prostate cancer.
Debes JD; Tindall DJ
Cancer Lett; 2002 Dec; 187(1-2):1-7. PubMed ID: 12359344
[TBL] [Abstract][Full Text] [Related]
18. Progesterone receptor in the prostate: A potential suppressor for benign prostatic hyperplasia and prostate cancer.
Chen R; Yu Y; Dong X
J Steroid Biochem Mol Biol; 2017 Feb; 166():91-96. PubMed ID: 27125450
[TBL] [Abstract][Full Text] [Related]
19. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
20. Androgens regulate prostate cancer cell growth via an AMPK-PGC-1α-mediated metabolic switch.
Tennakoon JB; Shi Y; Han JJ; Tsouko E; White MA; Burns AR; Zhang A; Xia X; Ilkayeva OR; Xin L; Ittmann MM; Rick FG; Schally AV; Frigo DE
Oncogene; 2014 Nov; 33(45):5251-61. PubMed ID: 24186207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
